Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy-Reference-Cited by-同舟云学术

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy

Published:2023-10 Issue: Volume:71 Page:63-68
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Nordenskjöld Anna^ORCID,Fohlin Helena^ORCID,Rosell Johan,Bengtsson Nils-Olof,Fornander Tommy,Hatschek Thomas,Lindman Henrik,Malmström Per,Rydén Lisa,Wallgren Arne,Stål Olle,Nordenskjöld Bo

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference23 articles.

1. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials;Early Breast Cancer Trialists' Collaborative;Lancet,2011

2. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. Swedish Breast Cancer Cooperative Group;J Natl Cancer Inst,1996

3. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Early Breast Cancer Trialists' Collaborative;Lancet,2005

4. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers;Fornander;Lancet,1989

5. Long-term effects of adjuvant tamoxifen and/or radiotherapy. The south Sweden breast cancer trial;Ryden;Acta Oncol,1992

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up;Acta Oncologica;2024-07-05